AcelRx wins U.S. patents for pain treatment
(Reuters) - AcelRx Pharmaceuticals said the U.S. patent office granted two patents on the specialty pharmaceutical company's methods for managing post-operative pain.
AcelRx said the notice of allowance from the U.S. Patent and Trademark Office could provide protection to its NanoTab technology for delivering a pain drug, sufentanil, till at least Feb, 2029.
A Notice of Allowance is issued after the USPTO decides that a patent can be granted after a company has applied for one.
AcelRx's shares closed at $3.40 on Tuesday on the Nasdaq.
(Reporting by Balaji Sridharan in Bangalore; Editing by Saumyadeb Chakrabarty)
- Alabama man gets $1,000 in police settlement, his lawyers get $459,000
- Two killed, four wounded in Washington state school shooting
- Two U.S. states to quarantine health workers returning from Ebola zones |
- NYC police say hatchet attack by Islam convert was terrorism |
- 'We won't pay,' furious Cameron tells EU over surprise bill |